Scioto Biosciences

Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics.

Scioto is developing innovative therapies devoted to having a transformative impact on the delivery of live bacterial therapeutics (LBTs).

 Scioto was founded in 2017 by Joe Trebley and Jim Schulz, as a partnership between Indiana business accelerator, Monon Bioventures (MBV) and AWRI with whom the company has a worldwide exclusive licensing agreement. The company is headquartered in Indianapolis, Indiana, with an office in Columbus, Ohio.

 

Scioto has developed a proprietary Activated Bacterial Therapeutics (ABT) platform for delivering best-in-class, live therapeutic bacteria to the gut. The solution is focused on the activation of beneficial bacteria that have the potential to advance healing for various diseases associated with the GI tract, Oncology and CNS indications.

 

Scioto Biosciences is backed by Genome & Company, National Institutes of Health, BioCrossroads, Elevate Ventures and others. The company raised $26.5M in Series B round on Aug 11, 2020. This brings Scioto's total funding to $31M to date.

 

 

  • Year founded: 2017
  • Funding Info: $31M over 4 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 2-10
  • Business Valuation: NA
  • City/Town: Indianapolis
  • State: Indiana
  • Country: United States
Related businesses